R2PHARMA produces and distributes radiopharmaceuticals for nuclear medicine diagnostics, utilizing cyclotron technology for PET imaging agents and offering lyophilized reagent kits for SPECT and PET-CT. The company also provides centralized radiopharmacy services to prepare and deliver patient-ready doses, ensuring consistent quality and availability for diagnostic imaging centers and hospitals.
Funding
Funding not disclosed
Founders
Product
Problem
The field of nuclear medicine requires specialized radiopharmaceuticals for accurate diagnostic imaging. Access to these critical materials can be limited by production capabilities and distribution networks, impacting the timely diagnosis and treatment of various diseases.
Solution
R2PHARMA provides a comprehensive suite of radiopharmaceutical solutions designed to support nuclear medicine diagnostics. The company leverages cyclotron technology for the production of PET and SPECT imaging agents, alongside a portfolio of lyophilized reagent kits. Additionally, R2PHARMA operates centralized radiopharmacies to prepare and distribute patient-ready doses, ensuring consistent quality and availability. This integrated approach aims to enhance diagnostic capabilities and patient care within the nuclear medicine sector.
Target Audience
The primary customers are nuclear medicine departments within hospitals, diagnostic imaging centers, and research institutions that require reliable access to radiopharmaceuticals for diagnostic procedures.
Features
- Cyclotron-produced radiopharmaceuticals for PET and PET-CT imaging, including FDG (18F), Florbetabeno (18F), and PSMA-based agents.
- Lyophilized reagent kits (Cold Kits) for SPECT and PET-CT imaging, covering a range of diagnostic applications such as myocardial perfusion, tumor localization, and renal function assessment.
- Centralized radiopharmacy services for the manipulation and distribution of personalized, patient-ready radiopharmaceutical doses.
- Adherence to Good Manufacturing Practices (GMP) and ANVISA authorization for all production and distribution facilities.
- Research and Development pipeline focused on introducing novel radiopharmaceuticals to the Brazilian market.
- Network of eight facilities across five states, including cyclotron plants, centralized radiopharmacies, and a lyophilized kit production facility.
- Distribution of products to over 420 nuclear medicine services in Brazil and export to more than 10 countries.